Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients

医学 托珠单抗 大动脉炎 内科学 回顾性队列研究 动脉炎 血管炎 类风湿性关节炎 疾病
作者
A. Mékinian,Lucie Biard,Lorenzo Dagna,Pavel Novikov,Carlo Salvarani,Olivier Espitia,Savino Sciascia,Martin Michaud,M. Lambert,José Hernández‐Rodríguez,N. Schleinitz,Abid Awisat,Xavier Puéchal,Achille Aouba,Helene Munoz Pons,Ilya Smitienko,Jean Baptiste Gaultier,Edwige Le Mouel,Y. Benhamou,Antoinette Perlat
出处
期刊:Rheumatology [Oxford University Press]
卷期号:61 (4): 1376-1384 被引量:34
标识
DOI:10.1093/rheumatology/keab635
摘要

To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK). A total of 209 patients with TAK [median age 29 years (interquartile range 7-62)], 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)] or tocilizumab [n = 77 (37%) with 121 lines; i.v. and s.c. in 95 and 26 cases, respectively]. A complete response at 6 months was evidenced in 101/152 (66%) patients on TNF-α antagonists and 75/107 (70%) patients on tocilizumab. Age ≥30 years [odds ratio 2.09 (95% CI 1.09, 3.99)] was associated with complete response, whereas vascular signs [OR 0.26 (95% CI 0.1, 0.65)], baseline prednisone ≥20 mg/day [OR 0.51 (95% CI 0.28, 0.93)] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvement [HR 2.44 (95% CI 1.06, 5.65) and 3.66 (1.18, 11.4), respectively] and systemic signs at baseline [HR 2.01 (95% CI 1.30, 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNF-α antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biologic targeted therapies [37 (21%) on TNF-α antagonists and 21 (17%) on tocilizumab (P = 0.4), respectively]. This large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Stageruner完成签到,获得积分10
刚刚
kiyo_v完成签到,获得积分10
刚刚
黄超超发布了新的文献求助10
1秒前
落寞剑成完成签到 ,获得积分10
1秒前
七子完成签到,获得积分10
1秒前
klio完成签到 ,获得积分10
2秒前
zzx396完成签到,获得积分0
3秒前
one完成签到 ,获得积分10
4秒前
十五完成签到,获得积分10
4秒前
ptjam完成签到 ,获得积分10
5秒前
神勇的晟睿完成签到 ,获得积分10
6秒前
6秒前
曾珍完成签到 ,获得积分10
6秒前
Muhi完成签到,获得积分10
6秒前
6秒前
自带蓝牙的土豆完成签到 ,获得积分10
7秒前
青羽落霞完成签到 ,获得积分10
8秒前
抹颜完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
13秒前
胡图图完成签到,获得积分10
14秒前
睡觉大王完成签到 ,获得积分10
15秒前
16秒前
16秒前
17秒前
17秒前
22秒前
玩命的十三完成签到 ,获得积分10
22秒前
寂寞的诗云完成签到,获得积分10
24秒前
我爱科研完成签到 ,获得积分10
24秒前
25秒前
Bin_Liu发布了新的文献求助10
26秒前
She完成签到,获得积分10
26秒前
29秒前
Raki完成签到,获得积分10
30秒前
22完成签到 ,获得积分10
30秒前
Echo_1995完成签到,获得积分10
33秒前
徐慕源完成签到,获得积分10
33秒前
able发布了新的文献求助10
34秒前
呜呜完成签到 ,获得积分10
35秒前
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022